Open-label Extension Denosumab Study in Children and Young Adults With Osteogenesis Imperfecta

 Osteogenesis imperfecta / Posted 11 months ago

To evaluate long-term safety of denosumab in subjects with pediatric osteogenesis imperfecta(OI) completing Study 20130173.

  • Study start date : 01/07/2018
  • Study end date : 01/03/2024
  • Wales-Based Study Contact : please speak to your clinician
Contact details

Research Site Birmingham B4 6NH Research Site Bristol BS2 8AEEngland medinfo@amgen.com bepartofresearch.nihr.ac.uk

No post found